&
Value Proposition
What if…
Technology existed that could
provide a comprehensive
physical evaluation of a person’s
health state, prioritizing areas of
concern in less than 5 minutes?
And what if…
This technology could detect
and determine levels of
severities of different disease
states and could reduce overall
diagnostic costs and increase
efficiency?
• This technology does exist. The
ClearView™ system is a highly
advanced diagnostic screening tool
that delivers an objective, real-time
assessment of organ system health.
• We believe the ClearView™ system
can provide the appropriate medical
personnel with a critical tool to enable
health care teams to view the impact
of diseases that are increasing in
prevalence around the world.
• Our proprietary system measures
and quantifies vulnerability within
the human body, and provides a
prioritization of organs at risk for
disease and those that have been
compromised through accident or
injury. The ClearView™ system can
also be used as an adjunct tool to
monitor treatment efficacy.
How It Works
• The science behind the ClearView™ system is based upon the intrinsic
electrical currents which are present in all living cells via the ion channel
movements, molecular processes, and biophotonic exchange. The ability
to measure these underlying currents allows for the revelation of valuable
system information relating directly to pathological and physiological
conditions.
• The ClearView™ system, a new, non-invasive measurement tool,
stimulates and captures unique images of electrophysiological signals
evoked from an individual’s body. These unique signals are then analyzed
through a series of proprietary and complex algorithms, and normalized
across a vast database.
• The result is a comprehensive health report providing visibility to the
functional dynamics of the patient’s cellular matrix including changes in
mitochondrial ATP energy production as manifested in physiological and
pathological conditions.
The ClearView System organs and systems at risk for
disease or dysfunction according to
The ClearView™ system consists of
physician diagnosis reached through
an imaging scanner and proprietary
standard of care testing such as
software. The patent pending
blood panels, X-rays, MRIs, and
software analyzes and interprets
PET scans. These early indications
the biophotonic emanation images
of capabilities demonstrate the
captured by the imaging scanner
substantial impact the technology
resulting in a comprehensive
can have on the healthcare system.
analysis of the body’s health, and
The nature of the software algorithm
an indication of whether or not the
allows for a platform distribution of
body is trending toward or actively
the ClearView technology, lending
involved in a disease process or
itself to a multi-focal business
trauma. The pertinent results are
opportunity.
provided in a comprehensive report
form, easy for the physician to read The ClearView system provides
and act on the information. physicians and those entrusted
Medical Therapeutic Targets:
with the medical care of others,
the opportunity to quickly and
Metabolic dysfunction leading to
economically gain an initial
metabolic syndrome, traumatic
understanding of patient disease
brain injury, and venous
states possibly leading to the
thromboembolism.
elimination or postponement of other
Athletics: Pre-screening of amateur expensive and invasive tests.
and professional athletes and post-
Medical Site of Care: Emergency
injury evaluation (concussion).
departments, urgent care clinics,
hospital in-patient and out-patient,
Armed Services: Pre-screening
of all enlistees to check viability for general practitioner offices, military
deployment and physical/mental field hospitals, sports training
capabilities, post-injury evaluation facilities, sports medicine clinics,
(concussion, trauma, level of injury). ambulance, EMT transport, nursing
homes, home health care.
Foundational clinical studies using
the ClearView system demonstrate
its ability to significantly correlate
Medical Market Opportunity
EPIC will target three primary verticals for
the use of ClearView™ technology:
•P
 redicting Risk for Metabolic Syndrome
(MetSyn): The early identification of
MetSyn as well as assessment of risk for
development of MetSyn can reduce the
risk of developing associated disease
patterns such as heart disease, diabetes,
cancer, and stroke. In a recent feasibility
study, the ClearView system demonstrated
97% accuracy in identifying metabolic
syndrome. Another potential ClearView
reporting outcome will be the identification
of early diagnostic risk factors that
help predict likelihood for developing
the disease.
•P
 redicting Risk for Traumatic Brain Injury
(TBI): The world is searching for a fast,
easy and accurate method to identify those
who have incurred a brain injury. Most
important is the real-time identification of
concussion. In a pilot study of 54 subjects,
the ClearView system was able to correctly
identify those with mild and moderate
concussions with 98% accuracy.
•P
 redicting Risk for Venous
Thromboembolism (VTE): VTE is
a common condition that affects an
estimated 300,000 to 600,000 people in
the United States each year1. Although
VTE is preventable, it is the third most
common cardiovascular illness after acute
coronary syndrome and stroke2. Because
several events can go undetected or may
be asymptomatic, misdiagnosing or even
neglecting a diagnosis can occur and may
be life-threatening. The ClearView system
may have the capability to detect a deep
vein thrombosis (DVT) and/or pulmonary
embolism (PE). A physician having the
ability to make an immediate diagnosis
quickly after triage, possibly replacing
current invasive and expensive diagnostic
techniques, is the goal. A feasibility study is
designed, approved and ready to accrue.
In a prior cardiovascular study, the
ClearView system was able to see VTE.
Each of these verticals represents a major
win within the overburdened healthcare
system that is looking for a fast, efficient,
and affordable method to assess patients in
real time. We believe the ClearView system
will provide the solution.
1 P
 ayne, AB, Miller CH, Hooper WC, Lally C,
Austin HD. High Factor VIII, von Willebrand
Factor, and Fibrinogen Levels and Risk of Venous
Thromboembolism in Blacks and Whites.
Ethnicity & Disease. 2014. Spring; 24(2):169-74.
2 G
 oldhaber SZ: Pulmonary embolism thrombolysis:
A clarion call for international collaboration.
J Am Coll Cardiol 1992;19(2):246-247.
Our Company
EPIC Research & Diagnostics, Inc., an Arizona corporation was established
in 2006 by Dr. Nancy Rizzo, and later merged into EPIC, a Delaware
corporation. The Company is working to develop and commercialize a
proprietary platform enabling healthcare professionals to detect disease
early and evaluate treatment efficacy.
Since the Company’s inception, it has focused on the development of
both hardware and software interfaces, Cloud®-based hosting and analytic
applications, and clinical trials to validate its claims for FDA submission.
With proceeds from this raise, the company intends to run a phase III
clinical study to validate ClearView’s ability to assess metabolic disruption
contributing to metabolic syndrome, and run phase II clinical studies to build
the models for the identification of traumatic brain injury, and pulmonary
embolism/ venous thrombosis (VTE). Notwithstanding the above, the
Company may use, in its sole discretion, the funds from this offering in any
distribution it chooses.
The company is based in Scottsdale, Arizona, and is a privately held
corporation, registered in the State of Delaware.
Technology Leadership
Nancy R. Rizzo, Ph.D., DABR
Founder, CEO and Chief Science Officer
Dr. Rizzo has 22 years of experience as a radiological biophysicist and is
an authority in the biophoton diagnostic technology field. Dr. Rizzo spent
13 years as Chief Clinical Radiological Therapeutic Physicist at Mayo Clinic.
Prior to Mayo, she practiced at the University of Michigan and Royal Oak
Beaumont. Dr. Rizzo has a B.S. in medical physics, M.S. in radiological
therapeutic physics, and Ph.D. in energy medicine/biophysics.
Intellectual Property The EPIC™ comparable terminology. Forward-looking
and ClearView™ names are trademarked. statements involve known and unknown
risks, uncertainties and other factors which
Mathematical algorithms and presentations
are trade secrets, and a provisional patent may cause the actual results, performance
is filed inclusive of more than 51 claims. or achievements of the Company, or
Since ClearView™ is a system comprised industry results, to be materially different
of both software and hardware, copyrights from any future results, performance or
and patents for the combined process achievements expressed or implied by the
of using the software and hardware forward-looking statements. Any instance of
a forward-looking statement in this brochure
together will also be pursued. A provisional
application was filed in August 2011, and an is only true at the time of publication of
international (Patent Cooperation Treaty) this brochure. EPIC is under no obligation
patent was filed in August 2012. to update these statements if conditions
change or unexpected events occur that
Projected Financials Available upon affect the information stated.
request with signed NDA. Statements of the diagnostic capability
of medical devices made to health care
Advisory Certain statements in this professionals may be regulated in the US
document constitute “forward-looking by the Food and Drug Administration. The
statements” within the meaning of SEC statements made herein are not directed to
rules. Forward-looking statements may be health care professionals, have not been
identified by the use of terminology like reviewed by the FDA, and merely express
“may,” “will,” “expect,” “believe,” “anticipate,” the informed opinions of EPIC management
“intend,” “designed,” “estimate,” “should,” as to the intended purposes of its future
or “continue,” the negatives thereof or products and services.
For more information on this offering, please contact:
Nancy R. Rizzo, Ph.D.
EPIC Research & Diagnostics, Inc.
7659 E. Pinnacle Peak, Suite 115 • Scottsdale, AZ 85255
&
480.477.5242 • www.epicdiagnostics.com